echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > FDA renews approval of the first interferon for the treatment of polycythemia vera

    FDA renews approval of the first interferon for the treatment of polycythemia vera

    • Last Update: 2021-12-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 12, 2021, the US Food and Drug Administration (FDA) approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adult patients with polycythemia vera (a blood disease that causes excessive red blood cell production)
    .

    ropeginterferon alfa-2b-njft is the first drug approved by the FDA to treat patients with polycythemia vera (regardless of the patient's previous treatment history) and the first interferon therapy specifically approved for polycythemia vera
    .

    Treatment of polycythemia vera includes bloodletting (phlebotomies; removing excess blood cells from a vein with a needle) and drugs that reduce the number of blood cells.
    Ropeginterferon alfa-2b-njft is one of the drugs that can reduce the number of blood cells

    .

    ropeginterferon alfa-2b-njft works by attaching to certain receptors in the body, triggering a chain reaction, thereby reducing the production of blood cells in the bone marrow
    .

    ropeginterferon alfa-2b-njft is a long-acting drug that patients receive subcutaneous injection every two weeks
    .

    If ropeginterferon alfa-2b-njft can reduce excess blood cells and maintain normal levels for at least one year, then the frequency of administration may be reduced to once every four weeks
    .

    The efficacy and safety of ropeginterferon alfa-2b-njft were evaluated in a 7.
    5-year multicenter, single-arm trial

    .

    In this trial, 51 adult patients with polycythemia vera received ropeginterferon alfa-2b-njft for an average of about five years
    .

    Complete hematological remission (red blood cell volume less than 45% and no recent exsanguination, normal white blood cell count and platelet count, normal spleen size and no blood clots) were used to evaluate the efficacy of ropeginterferon alfa-2b-njft
    .

    Overall, 61% of patients achieved complete hematological remission
    .

    ropeginterferon alfa-2b-njft can cause elevated liver enzymes, low white blood cell levels, low platelet levels, joint pain, fatigue, itching, upper respiratory tract infections, muscle pain, and flu-like illnesses
    .

    Side effects may also include urinary tract infections, depression, and transient ischemic attacks
    .

    Interferon therapy such as ropeginterferon alfa-2b-njft may cause or aggravate neuropsychiatric diseases, autoimmune diseases, ischemia (insufficient blood flow to a part of the body), and infectious diseases, leading to life-threatening or fatal complications
    .

    Patients who are not allowed to use ropeginterferon alfa-2b-njft include patients who are allergic to drugs, patients with severe mental disorders or a history of severe mental disorders, immunosuppressive transplant recipients, patients with autoimmune diseases or autoimmune diseases And patients with liver disease
    .

    Reference source: https:// Stamp "read the original text" and we will make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.